Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma-Reference-Cited by-同舟云学术

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma

Published:2010-04-01 Issue:12 Volume:116 Page:3054-3060
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kushner Brian H.,Kramer Kim,Modak Shakeel,Qin Li-Xuan,Cheung Nai-Kong V.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference36 articles.

1. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomized controlled trial;Berthold;Lancet Oncol.,2005

2. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomized trial;Pearson;Lancet Oncol.,2008

3. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study;Saylors;J Clin Oncol.,2001

4. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma;Garaventa;Cancer.,2003

5. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over 1 year of age;Donfrancesco;Acta Paediatr Suppl.,2004

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach;BMC Cancer;2024-09-12

2. Adolescent‐ and adult‐onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020;Pediatric Blood & Cancer;2024-05-22

3. Stage 4N neuroblastoma before and during the era of anti‐G_D2 immunotherapy;International Journal of Cancer;2023-08-21

4. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma;International Journal of Cancer;2023-05-29

5. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience;Frontiers in Oncology;2022-12-23